行情

NVIV

NVIV

InVivo
NASDAQ

实时行情|Nasdaq Last Sale

7.07
-0.18
-2.48%
交易中 13:37 02/20 EST
开盘
7.19
昨收
7.25
最高
7.33
最低
7.06
成交量
2.04万
成交额
--
52周最高
52.14
52周最低
3.693
市值
389.31万
市盈率(TTM)
-0.0066
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NVIV 新闻

  • 私募Sycamore Partners以5.25亿美元收购维秘55%股份
  • 新浪美股.4小时前
  • 飞利浦据称选择高盛和摩根大通负责家电业务的出售
  • 新浪财经.4小时前
  • 摩根士丹利以130亿美元全股票交易收购E*Trade
  • 新浪财经.4小时前
  • 黄金再刷7年新高!花旗认为可能还有25%的上涨空间
  • 新浪财经综合.5小时前

更多

所属板块

先进医疗设备和技术
-1.26%
医疗设备和用品
-0.96%

热门股票

名称
价格
涨跌幅

NVIV 简况

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
展开

Webull提供Invivo Therapeutics Holdings Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。